Peptic Ulcer Drugs Market Growth Forecast 2025-2034: FDA Approval and Advancements Drive Market Demand

The global peptic ulcer drugs market is expected to grow from USD 6.12 billion in 2024 to USD 8.89 billion by 2034, at a CAGR of 3.80%. The market growth is driven by the increasing prevalence of peptic ulcers, driven by Helicobacter pylori and NSAIDs use, alongside drug approvals such as Phathom Pharmaceuticals' new acid blocker. Key trends include robust R&D, government support, and healthcare advancements. North America leads market growth, with key players including Orion Corporation and Sanofi. Major insights cover market trends, segmentation by drug type, disease indication, distribution channel, and significant regional markets.

The global peptic ulcer drugs market is poised for significant growth, projected to expand from USD 6.12 billion in 2024 to USD 8.89 billion by 2034, at a compound annual growth rate (CAGR) of 3.80% [1]. This robust growth is driven by several key factors, including the increasing prevalence of peptic ulcers, driven by Helicobacter pylori infections and the use of nonsteroidal anti-inflammatory drugs (NSAIDs), as well as recent drug approvals such as Phathom Pharmaceuticals' new acid blocker.

The market is segmented by product type, disease indication, distribution channel, and region. Proton pump inhibitors (PPIs) and H2 antagonists are the primary drug types, while gastritis, gastric ulcer, and duodenal ulcer are the main disease indications. The market is dominated by North America, with key players such as Orion Corporation and Sanofi leading the way. The market's growth is further bolstered by robust research and development (R&D) activities, government support, and advancements in healthcare systems.

Key trends shaping the market include the increasing geriatric population, rising healthcare expenditure, and a surge in drug approvals by regulatory bodies. The FDA's approval of reformulated vonoprazan tablets by Phathom Pharmaceuticals in October 2023 is a notable example, offering promising Helicobacter pylori eradication rates. This approval is expected to significantly expand the market share of peptic ulcer drugs.

The market's segmentation by region reveals that North America dominates, followed by the EU-4 (Germany, France, Italy, Spain), and the United Kingdom. Japan and India are also expected to experience expedited growth during the forecast period, driven by their large populations and increasing healthcare expenditure.

In conclusion, the global peptic ulcer drugs market is expected to witness substantial growth in the coming years, driven by a combination of increasing prevalence, robust R&D, and favorable regulatory approvals. Investors and financial professionals should closely monitor this market for potential investment opportunities.

References:
[1] https://www.globenewswire.com/news-release/2025/07/23/3120020/0/en/Peptic-Ulcer-Drugs-Market-Forecast-Report-2025-2034-FDA-Approves-New-Helicobacter-pylori-Treatment-Market-Growth-Expected.html